JP-153

• Description :

  JP-153 is the Src-FAK-Paxillin signaling inhibitor. JP-153 inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473) . JP-153 reduces VEGF-induced migration and proliferation in retinal endothelial cells. JP-153 can be uesd for the study of neovascular eye disease[1].

• UNSPSC :

  12352005

• Target :

  FAK; Src

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Purity :

  99.45

• Solubility :

  DMSO : 200 mg/mL

• Smiles :

  O=C1OC(C2=CC(OC)=C(OC)C(OC)=C2)C3=CC=C4C=CC=CC4=C3N1

• Molecular Formula :

  C21H19NO5

• Molecular Weight :

  365.38

• References & Citations :

  [1]Toutounchian JJ, et al. Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis. Mol Pharmacol. 2017 Jan;91 (1) :1-13. doi: 10.1124/mol.116.105031. Epub 2016 Nov 9. Erratum in: Mol Pharmacol. 2017 Dec;92 (6) :627.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1802937-26-3]